Overexpression of a disintegrin and metalloproteinase 21 is associated with motility, metastasis, and poor prognosis in hepatocellular carcinoma

• Material Type: 博士論文
• Title: Overexpression of a disintegrin and metalloproteinase 21 is associated with motility, metastasis, and poor prognosis in hepatocellular carcinoma
• Author/Editor: Honda, Hiroki
• Publication, Distribution, etc.: 新潟大学
• Publication Date: 2018-03-23
• Publication Date (W3CDTF): 2018-03-23
• Alternative Title: Overexpression of a disintegrin and metalloproteinase 21 is associated with motility, metastasis, and poor prognosis in hepatocellular carcinoma; 肝細胞癌におけるADAM21の過剰発現は運動性,転移性および予後に関与する
• Degree grantor/type: 新潟大学
• Date Granted: 2018-03-23
• Date Granted (W3CDTF): 2018-03-23
• Dissertation Number: 甲第4385号
• Degree Type: 博士（医学）
• Conferring No. (Dissertation): 甲第4385号
• Text Language Code: eng
• Note (General): Cell motility plays an important role in intrahepatic metastasis of hepatocellular carcinoma (HCC), and predicts poor prognosis in patients. The present study investigated the role of a disintegrin and metalloproteinases (ADAMs) in HCC, since these proteins are known to be associated with cell motility. We confirmed the expression of 12 ADAMs with putative metalloproteinase activity in HCC cells, and established a KYN-2 HCC cell line stably expressing short interfering RNA against ADAM21 to investigate the effect of ADAM21 deficiency on HCC cell motility and metastasis in vitro and in vivo. We also examined ADAM21 expression in a cohort of 119 HCC patients by immunohistochemistry. ADAM21 was overexpressed in KYN-2 cells, and its knockdown reduced invasion, migration, proliferation, and metastasis relative to controls. In clinical specimens, ADAM21 positivity was associated with vascular invasion, large tumor size, high histological grade, and lower overall and recurrence-free survival as compared to cases that were negative for ADAM21 expression. A multivariate analysis revealed that ADAM21 positivity was an independent risk factor for overall (P = 0.003) and recurrence-free (P = 0.001) survival. These results suggest that ADAM21 plays a role in HCC metastasis and can serve as a prognostic marker for disease progression.; 学位の種類: 博士（医学）. 報告番号: 甲第4385号. 学位記番号: 新大院博（医）甲第784号. 学位授与年月日: 平成30年3月23日; Scientific Reports 7: 15485; 新大院博（医）甲第784号; 開始ページ : 1; 終了ページ : 10
• DOI: info:doi/10.1038/s41598-017-15800-z; https://doi.org/info:doi/10.1038/s41598-017-15800-z
• Persistent ID (NDL): info:ndljp/pid/11123967; https://dl.ndl.go.jp/pid/11123967
• Collection: 障害者向け資料
• Collection (Materials For Handicapped People:1): テキストデータ
• Collection (particular): 国立国会図書館デジタルコレクション > デジタル化資料 > 博士論文; https://dl.ndl.go.jp/collections/A00014
• Acquisition Basis: 博士論文（自動収集）
• Date Accepted (W3CDTF): 2018-08-03T23:36:01+09:00
• Date Created (W3CDTF): 2019-08-05
• Format (IMT): application/pdf
• Access Restrictions: 国立国会図書館内限定公開
• Service for the Digitized Contents Transmission Service: 図書館・個人送信対象外
• Availability of remote photoduplication service: 可
• Periodical Title (URI): http://hdl.handle.net/10191/50414
• Data Provider (Database): 国立国会図書館 : 国立国会図書館デジタルコレクション; https://dl.ndl.go.jp